Stock MOVE MEDACTA GROUP SA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Medacta Group SA

Equities

MOVE

CH0468525222

Market Closed - Swiss Exchange
Other stock markets
 16:31:30 26/04/2024 BST 		5-day change 1st Jan Change
110.6 CHF +2.03% Intraday chart for Medacta Group SA 0.00% -11.94%
03-13 Medacta Group SA Proposes Distribution CI
03-13 Medacta Group SA Provides Earnings Guidance for the Year 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.27 times its estimated earnings per share for the ongoing year.
  • With an enterprise value anticipated at 3.88 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
MEDACTA GROUP SA Stock Medacta Group SA
-11.94% 2.41B
B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MOVE Stock
  4. Ratings Medacta Group SA